← All trials
NCT06476392
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2024
- Primary completion
- Oct 15, 2026
- Completion date
- Nov 1, 2026
- First posted
- Jun 26, 2024
- Last posted
- Jul 10, 2024
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Southern DenmarkLead sponsor
- Aarhus UniversityCollaborator
- Erasmus University RotterdamCollaborator
- University of Southern DenmarkCollaborator
- Region of Southern DenmarkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.